Our areas of interest are Life Science and Health care. We use innovative proprietary software to create fast, safe and accurate diagnostic tools to be available all over the world.
Mission & Vision
We provide our technology for personalized, harmless, and accurate diagnostics to reduce invasive procedures in healthcare.
We believe in innovative medicine that is transformed by AI technology from invasive procedures to patient-friendly, accurate, and safe methods in diagnostics and treatment.
We push the boundaries of technology by delivering innovative solutions in the area of non-invasive diagnostics. We are target-driven.
For us, people come first. We share common goals and support one another in achieving them. We want no internal barriers. We engage and inspire our partners and each other.
We anticipate change and proactively manage it. We are flexible.
We raise safety standards in patient diagnostics. Always growing, we strive for the utmost precision in diagnosing heart disease.
Building on expert medical knowledge and advanced technologies, we have created a new alternative diagnostic tool in cardiology – an innovative software that provides functional and quantitative information about coronary artery stenosis severity. We help physicians and health care institutions to get to the forefront of digital transformation in diagnostics, making the diagnostic process fast, accurate and safe.
Accurate diagnosis in patients with suspected ischemic heart disease thanks to a combination of two non-invasive diagnostic tools: coronary computed tomography angiography and continuous non-invasive blood pressure monitoring. This makes it possible to produce a 3D model of the blood vessels, allowing for a detailed anatomical and functional evaluation of coronary arteries and simultaneously delivering patient-specific hemodynamic results (FFR values) across all coronary arteries.
Our unmatched technology based on computational fluid dynamics and artificial intelligence provides physicians and their patients with access to a safe, non-invasive and highly accurate diagnostics for coronary artery disease.
Establishment of the company.
Proof of Concept presentation.
Building the organization. Provisional patent application in the US.
Start of medical trials. MVP readiness of a cloud-based solution. First positive results of clinical trials. Final patent applications in the US and EU.
Continued clinical trials on 50 patients. CE-certification of innovative diagnostic method - Cardiolens FFR-CT Pro.
Establishing a five-year strategy. Increasing the engagement of investors. Establishment of an office in the Netherlands.
Clinical research. Finalization of work on a new version of the Cardiolens FFR-CT Pro diagnostic method. Development of commercial competence.
